XML 19 R7.htm IDEA: XBRL DOCUMENT v3.20.4
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Cash flows used in operating activities:    
Net loss $ (8,241) $ (10,887)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 366 896
Amortization of deferred financing costs and debt discount 584 550
In process research and development acquired from NanoTx Therapeutics 781 0
Change in fair value of liability instruments (2,400) (3,407)
Share-based compensation expense 247 127
Inventory write off 107 0
Noncash lease expense 3 12
Loss on sale of business 0 6,508
Allocation of issuance cost associated with warrants 0 1,233
Increases (decreases) in cash caused by changes in operating assets and liabilities:    
Accounts receivable 1,169 (1,203)
Inventories 0 259
Other current assets 126 (211)
Other assets 58 263
Accounts payable and accrued expenses (1,234) (28)
Deferred revenue 0 29
Other long-term liabilities 0 (47)
Net cash used in operating activities (8,434) (5,906)
Cash flows from (used in) investing activities:    
Purchases of property and equipment and intangible assets (93) (67)
In process research and development acquired from NanoTx Therapeutics (400) 0
Proceeds from sale of business 0 5,637
Net cash provided by (used in) investing activities (493) 5,570
Cash flows from financing activities:    
Principal payments of long-term obligations (5,307) (3,692)
Payment of financing lease liability (117) (131)
Proceeds from exercise of warrants 1,098 490
Proceeds from sale of common stock 4,007 15,964
Net cash (used in) provided by financing activities (319) 12,631
Effect of exchange rate changes on cash and cash equivalents 0 (4)
Net increase (decrease) in cash and cash equivalents (9,246) 12,291
Cash, cash equivalents, and restricted cash at beginning of period 17,592 5,301
Cash, cash equivalents, and restricted cash at end of period 8,346 17,592
Cash paid during period for:    
Interest 567 1,188
Supplemental schedule of non-cash investing and financing activities:    
Issuance costs paid in common stock 463 0
Common stock issued in payment for in process research and development 381 0
Unpaid offering cost 125 0
Reclassification of warrants liability to equity 4,504 794
Proceeds from sales of business, net, paid directly to lender for principal payment of long-term obligations 0 3,050
Offering cost paid in warrants 0 213
Fair value of Convertible Preferred Stock beneficial conversion feature $ 0 $ 554